优睿科
— UREIKO —

Data Sheet

WWW.UREIKO-CHEM.COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :Cabergoline EP Impurity D
Cat.No. :URK-V2462
CAS No. :85329-86-8
Molecular Formula :$C_{23}H_{32}N_4O$
Molecular Weight :380.53
Target :
Solubility :



Biological Activity

Cabergoline is a dopamine agonist medication used for the treatment of hyperprolactinemia and Parkinson's disease. It works by targeting dopamine receptors in the brain and stimulating their activity. However, during the production of cabergoline, impurities may arise, and one of them is Cabergoline EP Impurity D. In this article, we will briefly introduce Cabergoline EP Impurity D and its effects.

Cabergoline EP Impurity D is a cabergoline derivative that has not been fully studied yet. However, it has been identified as a by-product during the manufacturing process of cabergoline. This impurity is present in trace amounts and is classified as an unknown impurity.

Currently, there is very limited information on the pharmacological properties of Cabergoline EP Impurity D. However, it is known that cabergoline and its derivatives act on dopamine receptors expressed within the central nervous system. The same is expected for Cabergoline EP Impurity D.

In some studies, impurities in dopamine receptor agonist medications have been suggested to cause adverse effects such as hallucinations and delusions. However, this is not necessarily true for Cabergoline EP Impurity D, as no such effects have been reported yet.

References

1. European Pharmacopoeia. (2020). Cabergoline Impurities.
2. Bhatia, M. S., & Thakur, D. S. (2012). Dopamine agonist withdrawal syndrome: implications for patient care. Neurology India, 60(4), 373–375.
3. Vaidya, P., Chaudhari, M., & Gokhale, N. (2012). Medicinal Impurities in a Drug Product. In M. M. Cox & A. Viavattene-Christophe (Eds.), Handbook of Disinfectant and Antimicrobial Chemicals (pp. 635–670). CRC Press.

JACK@UREIKO-CHEM.COM